Waystar Holding Corp. Common Stock (WAY) fair value

ACCE thesis

Waystar sells revenue cycle management software and payment integration tools that hospitals and physician groups use to get paid faster, with its core platform processing claims, patient payments and eligibility checks. The structural case rests on that embedded position in provider workflows, which underpins a 69.1% gross margin and a 24.4% operating margin, both high for a healthcare IT name at this scale. Revenue is growing 18.1% a year, and the gap between a trailing P/E of 40.2 and a forward P/E of 12.8 says earnings are expected to rise sharply as recent investment and amortization costs roll off, which is the number to test first. At a $5.2B market cap with no index membership, the stock sits in a space where coverage is thin and the earnings inflection may not yet be priced in. The 3.8% ROE is low and reflects a balance sheet still carrying acquisition-related equity and debt, so the deeper look should focus on free cash flow conversion and the path to deleveraging. Score of 68/100 suggests the screen finds it attractive but not compelling on every factor.